SAN DIEGO — John P. Leonard, MD, of the department of medicine at Weill Cornell Medicine and NewYork-Presbyterian Hospital, provided insights into results of the randomized phase 3 GALLIUM study presented at the ASH Annual Meeting and Exposition.
In the study, Robert E. Marcus, MBBS, FRCP, FRCPath, of Kings College Hospital in London, and colleagues compared the safety and efficacy of either rituximab (Rituxan, Genentech) or obinutuzumab (Gazyva, Genentech) with chemotherapy followed by maintenance with the same agent as first-line therapy for patients with previously untreated follicular lymphoma.
Researchers calculated a higher 3-year PFS rate among patients assigned obinutuzumab (80% vs. 73.3%; HR = 0.66; 95% CI, 0.51-0.85).
An independent review committee also reported consistent benefit in favor of obinutuzumab for PFS, as well as additional time-to-event endpoints.
Obinutuzumab-treated patients experienced a higher rate of grade 3 to grade 5 adverse events (74.6% vs. 46.1%). Rates of fatal adverse events (4% vs. 3.4%) and adverse events that led to treatment discontinuation (16.3% vs. 14.2%) were comparable between treatment groups.
“This does not necessarily apply to all patients. Some patients opt not to have maintenance therapy, and we don’t have data with this particular antibody in this setting without maintenance,” Leonard said. “Additionally, I think this study will bring more information to light as to what are the preferred chemotherapy approaches to partner with an anti—CD20 antibody treatment,” Leonard said. “I think it will change care for some, but perhaps not all, patients with untreated follicular lymphoma.” – by Kristie L. Kahl
Marcus RE, et al. Abstract 6. Presented at: ASH Annual Meeting and Exposition; Dec. 3-6, 2016; San Diego.
Disclosure: Leonard reports no relevant financial disclosures.